www.ecancer.tv

Prof Mathias Rummel - Klinikum der Justus-Liebig-Universität, Giessen, Germany March 01, 2011 Prof Mathias Rummel discusses his research demonstrating the efficacy of bendamustine plus rituximab as a treatment for mantle cell lymphomas (MCL). Following the results presented at ASH 2009 revealing the superiority of bendamustine plus rituximab over CHOP plus rituximab as first line ...

www.ecancer.tv

Chair: Prof Meletios Dimopoulos - Univeristy of Athens, Greece; Prof Hermann Einsele - Medizinische Klinik II, Wurzburg, Germany; Prof Mario Boccadoro - University of Turin, Italy; Dr Maria-Victoria March 01, 2011 The panel discuss how the results of recent clinical trials have advanced our understanding of the optimal treatment for multiple myeloma. The development of new combinations containing drugs such as thalidomide, bortezomib and lenalidomide is helping clinicians achieve complete remission and ...

www.ecancer.tv

Prof Mathias Rummel - Klinikum der Justus-Liebig-Universität, Giessen, Germany March 01, 2011 Prof Mathias Rummel talks about the history of bendamustine from its origins in 1960’s East Germany to the modern trials evaluating the use of bendamustine and rituximab to treat lymphoproliferative diseases.

www.ecancer.tv

Prof Antonio Palumbo - Molinette Hospital, Turin, Italy and Prof Vincent Rajkumar - Mayo Clinic, Arizona, USA March 01, 2011 Prof Antonio Palumbo and Prof Vincent Rajkumar discuss some of the key research into myeloma that was presented at ASH 2010. This includes trials demonstrating that post transplant lenalidomide maintenance treatment dramatically improves progression free survival, a study comparing bortezomib ...

www.ecancer.tv

Prof Anton Hagenbeek - Academic Medical Center, Amsterdam, Netherlands February 23, 2011 Prof Anton Hagenbeek discusses the five and a half year results of the First-Line Indolent Trial (FIT) study. The randomised phase III FIT study evaluates the clinical benefits and safety of a single infusion of Zevalin (ibritumomab tiuxetan) in patients with previously untreated follicular ...